[Benign myocardial uptake of 99mTc-HMDP in prostate carcinoma: based on three cases]

Rev Esp Med Nucl. 2003 Jan-Feb;22(1):35-9. doi: 10.1016/s0212-6982(03)72139-9.
[Article in Spanish]

Abstract

We present three cases of patients with prostate carcinoma who underwent total body bone scintigraphy with 99mTc-Hydroxymethylene diphosphonate (99mTc-HMDP), showing myocardial uptake. Complementary diagnostic examinations were performed in these patients: cardiac (electrocardiogram and echocardiography), analysis of plasma electrolytes, including calcium, review of personal background of each patient to rule out associated disease which could have produced this uptake. No evidence of associated disease was found, processes such as heart disease, amyloidosis, hyperparathyroidism, previous chemotherapy or radiotherapy being rule out. Thus, we conclude that the myocardial uptake was secondary to the prostate carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / secondary*
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms / diagnostic imaging*
  • Bone Neoplasms / secondary*
  • Humans
  • Male
  • Myocardium / metabolism*
  • Prostatic Neoplasms / pathology*
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics*
  • Technetium Tc 99m Medronate / analogs & derivatives*
  • Technetium Tc 99m Medronate / pharmacokinetics*
  • Tissue Distribution

Substances

  • Radiopharmaceuticals
  • technetium Tc 99m hydroxymethylene diphosphonate
  • Technetium Tc 99m Medronate